Total
0
Shares
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham
CEO, James Graham
Source: Recce Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) has been granted a patent from the Chinese Patent Office
  • The patent is for the company’s antibiotic products RECCE 327 and RECCE 529
  • China is a large and influential pharmaceutical market, representing a value of approximately USD $86.78 million (about A$118 million)
  • The patent is the third to be awarded to the company, following the recent patent grant in Europe and Japan
  • On market close, Recce was up 11.5 per cent and trading at $1.07 per share

Recce Pharmaceuticals (RCE) have been granted a patent from the Chinese Patent Office.

The patent is for the company’s antibiotic product RECCE 327 and antiviral formulation RECCE 529.

China is one of the largest and most influential pharmaceutical markets in the
world with a value of approximately USD $86.78 million (about A$118 million).

Recce has been granted the Family 3 patent and it is the third to be awarded to the company, following the recent patent grants in Europe and Japan.

Additionally, there are other pharmaceutical markets around the world in advanced stages of independent patent reviews.

CEO James Graham said he was pleased with the Chinese patent.

“Recce’s intellectual property portfolio continues to grow in line with our business strategy and the unprecedented global infectious disease crisis
before us,” Mr Graham said.

“With this new patent granted in one of the largest pharmaceutical markets in the world, our market monopolies reinforce the unique opportunities among a significant range of both bacterial and viral pathogens.”

Yesterday, the company reported that RECCE 327 demonstrated  “outstanding efficacy” against flesh-eating bacteria.

The study found RCE’s synthetic anti-infective reduced the “flesh-eating” bacterial count of necrotizing fasciitis.

On market close, Recce was up 11.5 per cent and trading at $1.07 per share.

RCE by the numbers
More From The Market Herald

" Orthocell’s (ASX:OCC) rotator cuff tendon treatment proves successful

Orthocell’s (OCC) latest study results have revealed OrthoATI is much more effective than steroid injection when treating rotator cuff tendinopathy with intrasubstance tendon
Race Oncology (ASX:RAC) - MD and CEO Phillip Lynch

" Race Oncology (ASX:RAC) posts “remarkable” Zantrene results

Race Oncology (RAC) has released further interim results from the Zantrene preclinical heart safety research program.
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion (ASX:ALC) to raise $55m & acquire Silverlink

Alcidion (ALC) has announced plans to raise $55 million and buy patient software specialists, Silverlink PCS Software.
Actinogen Medical (ASX:ACW) - CEO & Managing Director, Dr Steven Gourlay

" Actinogen Medical (ASX:ACW) partners with Oxford University

Actinogen (ACW) has announced a collaboration with Oxford University researchers to investigate Xanamem and a condition called mild autonomous cortisol secretion (MACS).